First in Human Experience with the CroiValve DUO Novel Tricuspid Coaptation Valve: THE TANDEM I Trial

Wojciech Wojakowski presented First in Human Experience with the CroíValve DUO Novel Tricuspid Coaptation Valve TANDEM I Trial on 9th Jun ’23 at TVT, Phoenix, US.

The CroíValve DUO Tricuspid Coaptation Valve system consists of a prosthetic valve with coaptation skirt and an anchoring catherer system and stent.

The objective of the TANDEM I FIH Trial is to demonstrate safety and effectiveness of the DUO Coaptation Valve System in patients with severe symptomatic TR.

The investigators involved in the study found the procedure to be straightforward. Device delivery is simple, well tolerated and quick. There is no need for complex imaging and there is a very short learning curve.

Clinical outcomes: Significant symptom and QoL improvements out to 30d and 90d across all parameters (NYHA, KCCQ, 6MWT)

About Tricuspid Regurgitation

Tricuspid regurgitation (TR) is a severe heart condition that occurs when the tricuspid valve fails to close properly. This results in blood being pumped backwards into the right atrium and venous system causing debilitating symptoms.”

Full presentaion:https://www.tctmd.com/slide/first-human-experience-croivalve-duo-novel-tricuspid-coaptation-valve-ta...